Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

Blood

Volumn 119, Issue 23, 2012, Pages 5367-5373

  Pabst, Thomas ^a   Vellenga, Edo ^b   Van Putten, Wim ^c   Schouten, Harry C ^d   Graux, Carlos ^e   Vekemans, Marie Christiane ^f   Biemond, Bart ^g   Sonneveld, Peter ^c   Passweg, Jakob ^h   Verdonck, Leo ⁱ   Legdeur, Marie Cecile ^j   Theobald, Matthias ^k   Jacky, Emanuel ^l   Bargetzi, Mario ^m   Maertens, Johan ⁿ   Ossenkoppele, Gert Jan ^o   Löwenberg, Bob ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j Mesch Spectrum Twente   (Netherlands)

^k UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m CANTONAL HOSPITAL AARAU   (Switzerland)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 84862530664     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-389841     Document Type: Article

References (36)

1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
2. Ossenkoppele GJ, van der Holt B, Verhoef GE, et al. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group. Leukemia. 1999;13(8):1207-1213. (Pubitemid 29396580)
3. Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia: Kohseisho Leukemia Study Group. Blood. 1994;83(8):2086-2092. (Pubitemid 24112719)
4. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion highdose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood. 1992;79(9):2246-2255.
5. Frenette PS, Desforges JF, Schenkein DP, et al. Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. Am J Hematol. 1995;49(1):48-55.
6. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol. 1996;14(7):2150-2159. (Pubitemid 26230119)
7. Löwenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol. 1997;15(12):3496-3506.
8. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999;93(8):2478-2484. (Pubitemid 29181178)
9. Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo controlled trial (EMA 91 trial). Leukemia. 1999;13(8):1214-1220. (Pubitemid 29396581)
10. Rossi HA, O'Donnell J, Sarcinelli F, Stewart FM, Quesenberry PJ, Becker PS. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2002;16(3):310-315. (Pubitemid 34223690)
11. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743-752. (Pubitemid 37010778)
12. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-485. (Pubitemid 38140076)
13. Hofmann WK, Heil G, Zander C, et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol. 2004;83(8):498-503. (Pubitemid 39144750)
14. Amadori S, Suciu S, Jehn U, et al. Use of glycosylated human recombinant G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106(1):27-34. (Pubitemid 40967170)
15. Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21(3):453-461.
16. Terpstra W, Löwenberg B. Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia. 1997;11(3):315-327. (Pubitemid 27120979)
17. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia. 1988;2(12):810-813. (Pubitemid 19017107)
18. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood. 1989;73(5):1272-1278. (Pubitemid 19107433)
19. Greenberg P, Cox C, Lebeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
20. Mitelman F, ed. ICSN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
21. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24(1):17-31. (Pubitemid 27104901)
22. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107(1):69-79. (Pubitemid 29500811)
23. Löwenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(1):65-75.
24. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
25. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood. 1996;88(10):3675-3685. (Pubitemid 26383089)
26. Ohno R. Granulocyte colony-stimulating factor, granulocyte-macrophage colony stimulating factor and macrophage colony stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Leuk Res. 1998;22(12):1143-1154. (Pubitemid 29002988)
27. Bernasconi C, Alessandrino EP, Bernasconi P, et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol. 1998;102(3):678-683. (Pubitemid 28387049)
28. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia: AML Cooperative Study Group. N Engl J Med. 1995;332(25):1678-1683.
29. Gardin C, Chaibi P, de Revel T, et al. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colonystimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia: Club de Reflexion en Hematologie. Leukemia. 1997;11(1):16-21. (Pubitemid 27065044)
30. Ganser A, Heil G, Seipelt G, et al. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML). Ann Hematol. 2000;79(1):30-35. (Pubitemid 30157747)
31. Dombret H. Granulocyte colony-stimulating factor in combination with intensive chemotherapy in the treatment of acute myeloid leukemia. Leuk Res. 1998;22(12):1137-1142. (Pubitemid 29002987)
32. Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011;118(23):6037-6042.
33. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-1036.
34. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106(5):1867-1874. (Pubitemid 41208607)
35. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113(24):6206-6214.
36. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with Non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(28):4767-4773.